Option Care Health, Inc. (NASDAQ:OPCH) Receives Average Rating of “Moderate Buy” from Analysts

Option Care Health, Inc. (NASDAQ:OPCH) has been given an average rating of “Moderate Buy” by the eight analysts that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $33.00.

A number of analysts have recently commented on OPCH shares. UBS Group started coverage on Option Care Health in a report on Thursday, December 5th. They issued a “neutral” rating and a $26.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $30.00 target price (down previously from $31.00) on shares of Option Care Health in a research report on Friday, January 10th. JPMorgan Chase & Co. lifted their target price on Option Care Health from $40.00 to $41.00 and gave the company an “overweight” rating in a research report on Thursday. Jefferies Financial Group raised Option Care Health from a “hold” rating to a “buy” rating and lifted their target price for the company from $26.00 to $35.00 in a research report on Thursday, January 23rd. Finally, Bank of America raised Option Care Health from a “neutral” rating to a “buy” rating and lifted their target price for the company from $26.00 to $33.00 in a research report on Monday, January 13th.

Insiders Place Their Bets

In other Option Care Health news, insider Michael Bavaro sold 30,996 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the transaction, the insider now owns 44,974 shares of the company’s stock, valued at $1,495,835.24. The trade was a 40.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.64% of the company’s stock.

Hedge Funds Weigh In On Option Care Health

Institutional investors have recently bought and sold shares of the business. Westfield Capital Management Co. LP increased its position in Option Care Health by 10.2% during the third quarter. Westfield Capital Management Co. LP now owns 6,492,152 shares of the company’s stock worth $203,204,000 after buying an additional 599,589 shares during the last quarter. Global Alpha Capital Management Ltd. boosted its holdings in shares of Option Care Health by 108.3% during the third quarter. Global Alpha Capital Management Ltd. now owns 49,818 shares of the company’s stock worth $1,559,000 after acquiring an additional 25,905 shares during the period. Graypoint LLC bought a new stake in shares of Option Care Health during the fourth quarter worth approximately $1,161,000. Victory Capital Management Inc. boosted its holdings in shares of Option Care Health by 4,432.8% during the third quarter. Victory Capital Management Inc. now owns 1,621,593 shares of the company’s stock worth $50,756,000 after acquiring an additional 1,585,818 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Option Care Health during the fourth quarter worth approximately $327,000. Institutional investors and hedge funds own 98.05% of the company’s stock.

Option Care Health Stock Performance

Shares of Option Care Health stock opened at $34.01 on Friday. The firm has a market cap of $5.62 billion, a price-to-earnings ratio of 28.58, a price-to-earnings-growth ratio of 2.30 and a beta of 1.33. The stock’s 50-day moving average is $29.83 and its 200-day moving average is $28.18. Option Care Health has a one year low of $21.39 and a one year high of $34.85. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.